Safety and Immunogenicity of a Candidate Bioconjugate Vaccine Against Streptococcus Pneumoniae When Administered to Adult and Elderly Healthy Subjects. A Phase I Randomized Study.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Bioconjugate-pneumococcal-vaccine-LimmaTech-Biologics (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; First in man
- Sponsors LimmaTech Biologics
- 14 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 New trial record